Description | Acquisition Date | Cost |
Abiomed, Inc., CVR | 12/28/22 | $2,652 |
Abbreviations: | |
CVR | – Contingent Value Rights |
Name | Value, beginning of period | Purchases | Sales proceeds | Net realized gain (loss) | Change in unrealized appreciation (depreciation) | Value, end of period | Dividend income | Shares, end of period |
Short-Term Investments | ||||||||
Liquidity Fund, Institutional Class(1) | $1,165,477 | $27,431,428 | $(27,133,894) | $ — | $ — | $1,463,011 | $9,061 | 1,463,011 |
(1) | Represents investment in Morgan Stanley Institutional Liquidity Funds - Government Portfolio. |
Asset Description | Level 1 | Level 2 | Level 3(1) | Total |
Common Stocks | $379,674,945(2) | $ — | $ — | $379,674,945 |
Rights | — | — | 2,652 | 2,652 |
Short-Term Investments: | ||||
Affiliated Fund | 1,463,011 | — | — | 1,463,011 |
Securities Lending Collateral | 1,507,717 | — | — | 1,507,717 |
Total Investments | $382,645,673 | $ — | $2,652 | $382,648,325 |
(1) | None of the unobservable inputs for Level 3 assets, individually or collectively, had a material impact on the Fund. |
(2) | The level classification by major category of investments is the same as the category presentation in the Schedule of Investments. |